Shots:
- The US FDA has approved AbbVie‘s Decnupaz (pivekimab sunirine-pvzy) for the treatment of adults with BPDCN
- Approval was supported by the global P-I/II (CADENZA) trial in 84 pts with CD123+ hematologic malignancies, incl. BPDCN, where pts received Decnupaz in both frontline (n=33) & relapsed/refractory (R/R) settings (n=51) without active CNS disease
- Trial reported a 69.7% composite CR rate with 9.7mos. mDoR in newly diagnosed BPDCN pts, with 13 pts subsequently underwent stem cell transplant, while R/R pts achieved a 15.7% composite CR rate with 9.2mos. mDoR, with 6 pts able to receive post-study stem cell transplant
Ref: PRnewswire | Image: AbbVie | Press Release
Related News: AbbVie Reports the US FDA’s NDA submission of Tavapadon to Treat Parkinson’s Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
